COSMOS-CRC-03: ctDNA and Recurrence in Colorectal Cancer

Opinion
Video

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

New Blood Test Algorithm Shows Sensitivity, Specificity in CRC Screening

Russ Conroy
September 9th 2025
Article
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
September 9th 2025
Podcast
The median disease-free survival was 9.41 months in the TAS-102 cohort compared with 5.75 months in the synthetic control arm.

Though TAS-102 Achieved ctDNA Clearance, More Work is Needed

Tim Cortese
September 9th 2025
Article
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
September 9th 2025
Podcast
Significantly improved survival was observed with oxaliplatin among patients 60 to 70 years of age with stage III CRC, but not those older than 70 years.

Oxaliplatin Elicits Improved Survival in Select Patients With Stage III CRC

Roman Fabbricatore
September 9th 2025
Article
Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.

Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures

Roman Fabbricatore
September 9th 2025
Article